Levels of plasma thrombomodulin are increased in atheromatous arterial disease

Seigneur, M.; Dufourcq, Pascale; Conri, C.; Constans, J.; Mercié, P.; Pruvost, Annie; Amiral, Jean; Midy, D.; Jc, Baste; Boisseau, M. R.

doi:10.1016/0049-3848(93)90116-6

Cited by 104 publications

(63 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some findings in hypertension suggest that TM is released into the plasma only by true endothelial cell damage during development of vascular complications. 10,14,[18][19][20] . Probably a certain degree of endothelial injury is necessary for its plasma increase.…”

Section: Discussionmentioning

confidence: 99%

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Remková

Kratochvílová

2002

J Hum Hypertens

View full text Add to dashboard Cite

The aim of the study was to investigate the effect of therapy by rilmenidine on endothelial and platelet function in 23 patients with the early stages of untreated essential hypertension. The measurements were carried out before therapy, after 1 week of placebo administration, after 1 week, after 1 month and after 3 months of therapy. After 1 week of therapy both systolic (SBP) and diastolic blood pressure (DBP) were reduced (P Ͻ 0.001) all over the study period. Plasma thrombomodulin (TM) and von Willebrand factor (vWF) as indicators of endothelial dysfunction, and plasma ␤-thromboglobulin (␤TG) as an indicator of in vivo platelet activation, were investigated. Fibrinogen as a risk factor for vascular changes was also assayed. Platelet aggregation without stimulation (spontaneous, SPA) and induced by adre-

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Remková

Kratochvílová

2002

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…Endothelial dysfunction is a central feature of current models of atherogenesis [24]. Increased vWF and TM plasma concentrations probably reflect ongoing endothelial injury [11][12][13][14][15][16], Furthermore, high plasma vWF levels have been shown to predict a poor cardiovascular prognosis in survivors of myo cardial infarction [12] and in patients with non insulin-dependent diabetes mellitus [13]. The nature of the link between atherosclerosis and vWF and TM is not known with certainty.…”

Section: Van Den Berg Et Almentioning

confidence: 99%

“…A gold standard for endothelial dysfunction is not available; we therefore measured plasma levels of three endo thelium-derived proteins involved in the regulation of haemostasis, i.e. von Willebrand factor (vWF), thrombomodulin (TM) and tissue-type plasminogen activator (tPA), because in vitro and in vivo data suggest that endothelial injury is associated with increased plasma levels of these proteins [11][12][13][14][15][16][17][18]. In addition, we investigatèd the effects of treatment with pyridoxine plus folic acid on homocysteine meta bolism and endothelial function.…”

Section: Introductionmentioning

confidence: 99%

Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease

Berg¹,

Boers²,

Franken³

et al. 1995

Eur J Clin Investigation

188

View full text Add to dashboard Cite

Abstract. Hyperhomocysteinaemia, defined as an abnormally high plasma homocysteine concentration after an oral methionine load, is common in young ( ^ 50 years) patients with peripheral arterial occlusive disease. It is thought to predispose to atherosclerosis by injuring the vascular endothelium. Treatment with pyridoxine and/or folic acid may lower plasma homo cysteine levels, In mildly hyperhomocysteinaemic patients with peripheral arterial occlusive disease, we studied the effect of daily treatment with pyridoxine (250 mg) plus folic acid (5 mg) on homocysteine metabolism (i.e. plasma concentrations in the fasting state and after methionine loading, in 48 patients) and on endothelial function (in 18 patients), Endothelial function was estimated as the plasma concentrations of the endothelium-derived proteins, von Willebrand factor (vWF), thrombomodulin (TM), and tissue-type plasminogen activator (tPA). At baseline, fasting homocysteine levels were above normal in 24 of the 48 patients (50%); post-load levels, by definition, were above normal in 100% of patients. After 12 weeks of treatment, fasting and post-load levels were normal in 98 and 100% of patients, respectively. Endothelial function was assessed in 18 patients who completed 1 year of treatment. At baseline, median vWF (235%) and TM (57'1 ngm L"1) levels were above normal. At follow-up, vWF levels had decreased to 170% (p = 0*01) and TM levels had decreased to 49ngmL-1 (P = 0*04). tPA levels were normal at baseline and did not change. Endothelial dysfunction is present in young patients with peripheral arterial occlusive disease and hyperhomocysteinaemia. Pyri doxine plus folic acid treatment normalizes homocys teine metabolism in virtually all patients, and appears to ameliorate endothelial dysfunction.

show abstract

“…Increased concentrations of hemostatic endothelial surface molecules such as thrombomodulin (TM), 4,5 von Willebrand factor (vWF) 5,6 and tissue plasminogen activator antigen (t-PAag) 7 have been demonstrated in plasma from patients with atherosclerotic disease.…”

mentioning

confidence: 99%

The Effect of Supplementation With Omega-3 Fatty Acids on Soluble Markers of Endothelial Function in Patients With Coronary Heart Disease

Johansen

Seljeflot

Høstmark

et al. 1999

ATVB

156

View full text Add to dashboard Cite

Abstract-During progression of atherosclerosis the overlying endothelial cells alter their expression of some surface molecules. Circulating levels of such molecules may be quantified. We investigated the effect of omega-3 fatty acids (n-3 FA) on the levels of tissue plasminogen activator antigen, von Willebrand factor, and the soluble forms of thrombomodulin, P-selectin, E-selectin, and vascular cell adhesion molecule-1 in 54 patients with coronary heart disease. Twenty-three of the patients had taken 5.1 g/d n-3 FA for 6 months (group I) and 31 were given corn oil as placebo (group II). For another 4 weeks ("the study period") they all got 5.1 g/d of n-3 FA. Compliance was confirmed by demonstration of changes in relevant fatty acids in serum phospholipids. At baseline, significant differences between the groups were found with lower median values of von Willebrand factor (128% versus 147%) and soluble thrombomodulin (24.9 versus 32.5 ng/mL) and higher median values of soluble E-selectin (41.4 versus 35.5 ng/mL) and soluble vascular cell adhesion molecule-1 (573 versus 473 ng/mL) in group I. During the study period differences in changes between the groups were found; tissue plasminogen activator antigen and soluble thrombomodulin decreased (P for difference between the groups 0.001 and 0.015, respectively), whereas soluble E-selectin and soluble vascular cell adhesion molecule-1 increased (P for difference between the groups Ͻ0.01 for both) in group II relative to group I. Our results indicate that n-3 FA supplementation decreases hemostatic markers of atherosclerosis, whereas markers of inflammation may be increased. The latter may be the result of lipid peroxidation as a simultaneous decrease of vitamin E and increase in thiobarbituric acid-reactive substances were observed. (Arterioscler Thromb Vasc Biol.

show abstract

Levels of plasma thrombomodulin are increased in atheromatous arterial disease

Cited by 104 publications

References 27 publications

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease

The Effect of Supplementation With Omega-3 Fatty Acids on Soluble Markers of Endothelial Function in Patients With Coronary Heart Disease

Contact Info

Product

Resources

About